Прегледај по Аутор "Gutić, Medo"

Сада се приказује 1 - 1 од 1
  • Сличица
    Ставка
    Cost-effectiveness of ambroxol in the treatment of Gaucher disease type 2
    (De Gruyter, 2024) Milosavljević, Miloš N.; Gutić, Medo; Janjić, Vladimir; Veselinović, Slađana; Djordjić, Milan; Ivanović, Radenko; Milosavljević, Jovana; Janković, Slobodan M.
    Objective ‒ Our aim was to compare the costs and efficacy of ambroxol in combination with imiglucerase with the costs and efficacy of imiglucerase only in the treatment of Gaucher disease type 2 (GD2) in the socio-economic settings of the Republic of Serbia, an upper-middle-income European economy. Methods ‒ The perspective of the Serbian Republic Health Insurance Fund was chosen for this study, and the time horizon was 6 years. The main outcomes of the study were quality-adjusted life years gained with ambroxol + imiglucerase and comparator, and direct costs of treatment. The study was conducted through the generation and simulation of the Markov chain model. The model results were obtained after Monte Carlo microsimulation of a sample with 1,000 virtual patients. Results ‒ Treatment with ambroxol in combination with imiglucerase was cost-effective when compared with imiglucerase only and was associated with positive values of net monetary benefit regardless of the onset of the disease. Such beneficial result for ambroxol and imiglucerase combination is primarily driven by the low cost of ambroxol and its considerable clinical effectiveness in slowing the progression of neural complications of GD2. Conclusion ‒ If ambroxol and imiglucerase are used in combination for the treatment of GD2, it is more cost-effective than using imiglucerase alone.